Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a less invasive hip surgery speed up recovery?

NCT ID NCT05147207

Disease control Sponsor: Dr. Gavin Wood Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial compares two surgical approaches for total hip replacement: the minimally invasive SuperPATH technique and the conventional posterior approach. Adults with hip arthritis or related conditions are randomly assigned to one of the two procedures. The study tracks recovery through functional tests, pain scores, and return to work over two years, aiming to see if the less invasive method offers meaningful advantages.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Minimally invasive surgical procedure (SuperPATH approach) for total hip replacement
What this could lead to
If SuperPATH proves better, it could mean faster recovery, less pain, and quicker return to daily activities after hip replacement.
What could go wrong
This is a small, single-center trial, and results may not apply to all patients. The procedure is technically demanding and may carry risks similar to standard surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

45 people

The number who actually took part.

Started

Apr 2017

Finished

Jun 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis; * Inflammatory degenerative joint disease including rheumatoid arthritis; * Correction of functional deformity. * Subject is skeletally mature (21 years of age or older); * Subject is a candidate to be implanted with the specified combination of components; * Subject is willing and able to complete required study visits and assessments; * Subject plans to be available through the follow-up visits; * Subject is willing to sign the approved informed consent document. * Subjects with a previous THA in the contralateral hip are eligible for enrollment provided it has been at least 1 year since the contralateral THA and the contralateral THA is asymptomatic and not pending revision. Simultaneous bilateral THA subjects will not be permitted to enroll. Exclusion Criteria: * Subject has overt infection or distant foci of infections; * Subject has rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram; * Subject with inadequate neuromuscular status (e.g. prior paralysis, fusion and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable; * Subject has a neuropathic joints; * Subject has hepatitis or HIV infection; * Subject has a neurological or musculoskeletal disease that may adversely affect gait or weight-bearing; * Subject is currently enrolled in another clinical investigation that could affect the endpoints of this study; * Subject is unwilling or unable to sign the informed consent document; * Subject has documented substance abuse issues; * Subject has a body mass index (BMI) of greater than 40;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Avascular necrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

avascular necrosis osteoarthritis rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hip arthropathy Surgical approach

Contacts and locations

Locations

  • Kingston General Hospital

    Kingston, Ontario, K7L 2V7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.